. Cette-Étude-randomisée, en double aveugle a duré 12 semaines Quatre-vingt-onze patients ont été inclus dans cette étude (57 hommes

. En-une-heure-de-traitement-par-le-ticagrélor, IAP a été supérieure à l'inhibition maximum atteinte par le clopidogrel. Dans le groupe ticagrélor, l'IAP ne diffère pas entre 2 et 8 heures, alors que dans le groupe clopidogrel, p.2

L. Cruz, G. Castaneda-hernandez, and A. Navarrete, ) reduces salicylate bioavailability after oral aspirin administration in the rat, Canadian Journal of Physiology and Pharmacology, vol.77, issue.6, pp.441-447, 1999.
DOI : 10.1139/y99-032

M. Verstaete, C. Prentice, and M. Samama, A European View on the North American Fifth Consensus on Antithrombotic Therapy, Chest, vol.117, issue.6, pp.1755-70, 2000.
DOI : 10.1378/chest.117.6.1755

C. Patrono, Aspirin resistance: definition, mechanisms and clinical read-outs, Journal of Thrombosis and Haemostasis, vol.73, issue.8, pp.1710-1713, 2003.
DOI : 10.1046/j.1538-7836.2003.00284.x

P. Gum, K. Kottke-marchant, and E. Poggio, Profile and prevalence of aspirin resistance in patients with cardiovascular disease, The American Journal of Cardiology, vol.88, issue.3, pp.230-235, 2001.
DOI : 10.1016/S0002-9149(01)01631-9

A. Weber, K. Zimmermann, and J. Meyer-kirchrath, Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance, The Lancet, vol.353, issue.9156, pp.900-901, 1999.
DOI : 10.1016/S0140-6736(99)00498-5

J. Vane, Y. Bakhle, and R. Botting, CYCLOOXYGENASES 1 AND 2, Annual Review of Pharmacology and Toxicology, vol.38, issue.1, pp.97-120, 1998.
DOI : 10.1146/annurev.pharmtox.38.1.97

A. Michelson, M. Furman, and P. Goldschmidt-clermont, Platelet GP IIIa PlA Polymorphisms Display Different Sensitivities to Agonists, Circulation, vol.101, issue.9, pp.1013-1021, 2000.
DOI : 10.1161/01.CIR.101.9.1013

G. Cooke, P. Bray, and J. Hamlington, PlA2 polymorphism and efficacy of aspirin, The Lancet, vol.351, issue.9111, p.1253, 1998.
DOI : 10.1016/S0140-6736(05)79320-X

J. Harbison, H. Adams, and J. Grotta, Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study, Stroke, vol.23, issue.12, pp.1723-1730, 1992.
DOI : 10.1161/01.STR.23.12.1723

M. Gent, J. Easton, and C. Vladimir, The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke . The Lancet, pp.1215-1235, 1989.

L. Janzon, D. Bergquist, and J. Boberg, Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study, Journal of Internal Medicine, vol.296, issue.Suppl., pp.301-309, 1990.
DOI : 10.1111/j.1365-2796.1990.tb00164.x

M. Cattaneo, ADP receptor antagonists, pp.1127-1171, 2007.

K. Schrör, Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel, Vascular Medicine, vol.17, issue.3, pp.247-51, 1998.
DOI : 10.1177/1358836X9800300312

J. Mega, S. Close, and S. Wiviott, Cytochrome P-450 Polymorphisms and Response to Clopidogrel, New England Journal of Medicine, vol.360, issue.4, pp.354-62, 2009.
DOI : 10.1056/NEJMoa0809171

J. Mega, J. Thakuria, and C. Cannon, Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: insights from the CLARITY-TIMI 28 genomic study, 2008.

S. Wiviott, E. Antman, and C. Gibson, Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis, Myocardial Infarction, pp.627-662, 2006.

D. Trenk, W. Hochholzer, and M. Fromm, Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents, Journal of the American College of Cardiology, vol.51, issue.20, pp.1925-1959, 2008.
DOI : 10.1016/j.jacc.2007.12.056

J. Collet, J. Hulot, and A. Pena, Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study, The Lancet, vol.373, issue.9660, pp.309-326, 2009.
DOI : 10.1016/S0140-6736(08)61845-0

D. Sibbing, W. Hochholzer, and D. Trenk, Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention, European Heart Journal, vol.30, issue.8, pp.916-938, 2009.
DOI : 10.1093/eurheartj/ehp041

B. Giusti, M. Gori, and R. Marcucci, Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis, The American Journal of Cardiology, vol.103, issue.6, pp.806-817, 2009.
DOI : 10.1016/j.amjcard.2008.11.048

T. Simon, C. Verstuyft, and M. Mary-krause, Genetic Determinants of Response to Clopidogrel and Cardiovascular Events, New England Journal of Medicine, vol.360, issue.4, pp.363-75, 2009.
DOI : 10.1056/NEJMoa0808227

M. Gent, D. Beaumont, and J. Blanchard, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events, Lancet, vol.348, pp.1329-1368, 1996.

S. Ysuf, G. Tognoni, and S. Mehta, The clopidogrel in unstable angina to prevent recurrent events of trials invastigatiors. Effect of clopidogrel in addition to aspirin in patients with ACS without STelevation, N Eng J Med, vol.345, pp.494-502, 2001.

W. Kuliczkowski, A. Witkowski, and L. Polonski, Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology, European Heart Journal, vol.30, issue.4, pp.426-461, 2009.
DOI : 10.1093/eurheartj/ehn562

P. Gurbel, K. Bliden, and J. Saucedo, Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction, Journal of the American College of Cardiology, vol.53, issue.8, pp.648-57, 2009.
DOI : 10.1016/j.jacc.2008.10.045

M. Price, J. Coleman, and S. Steinhubl, Onset and Offset of Platelet Inhibition After High-Dose Clopidogrel Loading and Standard Daily Therapy Measured by a Point-of-Care Assay in Healthy Volunteers, The American Journal of Cardiology, vol.98, issue.5, pp.681-685, 2006.
DOI : 10.1016/j.amjcard.2006.03.054

J. Brandt, C. Payne, and S. Wiviott, A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation, American Heart Journal, vol.153, issue.1, pp.9-16, 2007.
DOI : 10.1016/j.ahj.2006.10.010

A. Sugidachi, T. Ogawa, and A. Kurihara, The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel?s active metabolite, Journal of Thrombosis and Haemostasis, vol.25, issue.2, pp.1545-51, 2007.
DOI : 10.1073/pnas.0510446103

J. Jakubowski, C. Payne, and Y. Li, A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry, Thrombosis and Haemostasis
DOI : 10.1160/TH07-09-0555

T. Jernberg, C. Payne, and K. Winters, Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease, European Heart Journal, vol.27, issue.10, pp.1166-73, 2006.
DOI : 10.1093/eurheartj/ehi877

L. Wallentin, C. Varenhorst, and S. James, Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease, European Heart Journal, vol.29, issue.1, pp.21-30, 2008.
DOI : 10.1093/eurheartj/ehm545

S. Wiviott, E. Antman, and K. Winters, Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial, Circulation, vol.111, issue.25, pp.3366-73, 2005.
DOI : 10.1161/CIRCULATIONAHA.104.502815

S. Wiviott, D. Trenk, and A. Frelinger, Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial, Circulation, vol.116, issue.25, pp.2923-2955, 2007.
DOI : 10.1161/CIRCULATIONAHA.107.740324

S. Wiviott, E. Braunwald, and C. Mccabe, Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes, New England Journal of Medicine, vol.357, issue.20, pp.2001-2016, 2007.
DOI : 10.1056/NEJMoa0706482

B. Springthorpe, A. Bailey, and P. Barton, From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis, Bioorganic & Medicinal Chemistry Letters, vol.17, issue.21, pp.6013-6021, 2007.
DOI : 10.1016/j.bmcl.2007.07.057

J. Van-giezen, L. Nilsson, and P. Berntsson, independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation, Journal of Thrombosis and Haemostasis, vol.50, issue.9, pp.1556-65, 2009.
DOI : 10.1111/j.1538-7836.2009.03527.x

D. Capodanno, K. Dharmashankar, and D. Angiolillo, receptor antagonist, Expert Review of Cardiovascular Therapy, vol.8, issue.2, pp.151-159, 2010.
DOI : 10.1586/erc.09.172

R. Owen, N. Serradell, and B. J. Azd6140, AZD6140, Drugs of the Future, vol.32, issue.10, pp.845-53, 2007.
DOI : 10.1358/dof.2007.032.10.1133832

T. Phd, M. Mitchell, and K. Butler, Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers, J Clin Pharm Ther, 2011.

K. Butler and R. Teng, Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment, The Journal of Clinical Pharmacology, vol.20, issue.7, pp.978-87, 2011.
DOI : 10.1177/0091270010379409

K. Butler and R. Teng, Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Severe Renal Impairment, The Journal of Clinical Pharmacology, vol.104, issue.9, 2011.
DOI : 10.1177/0091270011415526

C. Cannon, S. Husted, and R. Harrington, Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non???ST-Segment Elevation Acute Coronary Syndrome, Journal of the American College of Cardiology, vol.50, issue.19, pp.1844-51, 2007.
DOI : 10.1016/j.jacc.2007.07.053

D. Dennis, M. Raatikainen, and J. Martens, Modulation of Atrioventricular Nodal Function by Metabolic and Allosteric Regulators of Endogenous Adenosine in Guinea Pig Heart, Circulation, vol.94, issue.10, pp.2551-2560, 1996.
DOI : 10.1161/01.CIR.94.10.2551

J. Shryock and L. Belardinelli, Adenosine and Adenosine Receptors in the Cardiovascular System: Biochemistry, Physiology, and Pharmacology, The American Journal of Cardiology, vol.79, issue.12, pp.2-10, 1997.
DOI : 10.1016/S0002-9149(97)00256-7

R. Storey, S. Husted, and R. Harrington, Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes, Journal of the American College of Cardiology, vol.50, issue.19, pp.1852-1858, 2007.
DOI : 10.1016/j.jacc.2007.07.058

P. Gurbel, K. Bliden, and K. Butler, Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study, Circulation, vol.121, issue.10, pp.1188-99, 2010.
DOI : 10.1161/CIRCULATIONAHA.109.919456

A. Paul, K. Bliden, and K. Butler, Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study, Circulation, vol.120, pp.2577-85, 2009.

C. Cannon, R. Harrington, and S. James, Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study, The Lancet, vol.375, issue.9711, pp.283-93, 2010.
DOI : 10.1016/S0140-6736(09)62191-7

E. Braunwald, E. Antman, and J. Beasley, ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina), Circulation, vol.106, issue.14, pp.1366-74, 2002.
DOI : 10.1161/01.CIR.0000037106.76139.53

E. Kapetanakis, D. Medlam, and K. Petro, Effect of Clopidogrel Premedication in Off-Pump Cardiac Surgery: Are We Forfeiting the Benefits of Reduced Hemorrhagic Sequelae?, Circulation, vol.113, issue.13, pp.1667-74, 2006.
DOI : 10.1161/CIRCULATIONAHA.105.571828

A. Bavry and A. Lincoff, Is Clopidogrel Cardiovascular Medicine's Double-Edged Sword?, Circulation, vol.113, issue.13, pp.1638-1678, 2006.
DOI : 10.1161/CIRCULATIONAHA.105.617175

S. James, D. Angiolillo, and J. Cornel, Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial, European Heart Journal, vol.31, issue.24, pp.3006-3022, 2010.
DOI : 10.1093/eurheartj/ehq325

G. Montalescot and S. J. , Ticagrelor in the Renal Dysfunction Subgroup: Subjugated or Substantiated?, Circulation, vol.122, issue.11, pp.1049-52, 2010.
DOI : 10.1161/CIRCULATIONAHA.110.974683

L. Wallentin, S. James, and R. Storey, Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial, The Lancet, vol.376, issue.9749, pp.1320-1328, 2010.
DOI : 10.1016/S0140-6736(10)61274-3

L. Bonello, S. Armero, A. Mokhtar, and O. , Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19*2Loss of Function Polymorphism, Journal of the American College of Cardiology, vol.56, issue.20, pp.1630-1636, 2010.
DOI : 10.1016/j.jacc.2010.07.004

J. Mega, S. Close, and S. Wiviott, Cytochrome P-450 Polymorphisms and Response to Clopidogrel, New England Journal of Medicine, vol.360, issue.4, pp.354-62, 2009.
DOI : 10.1056/NEJMoa0809171

J. Hulot, J. Collet, and S. J. , Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration, Journal of the American College of Cardiology, vol.56, issue.2, p.13443, 2010.
DOI : 10.1016/j.jacc.2009.12.071

F. Sofi, B. Giusti, and R. Marcucci, Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis, The Pharmacogenomics Journal, vol.93, issue.3, pp.199-206, 2011.
DOI : 10.1111/j.1538-7836.2008.03004.x

D. Sibbing, W. Koch, and D. Gebhard, Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement, Circulation, vol.121, issue.4, p.5128, 2010.
DOI : 10.1161/CIRCULATIONAHA.109.885194

A. Owen, C. Goldring, and P. Morgan, Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver, British Journal of Clinical Pharmacology, vol.58, issue.210, p.36570, 2005.
DOI : 10.1067/mcp.2002.127739

S. Hoffmeyer, O. Burk, V. Richter, and O. , Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc Natl Acad Sci, vol.97, p.34738, 2000.

D. Taubert, V. Beckerath, N. Grimberg, and G. , Impact of P-glycoprotein on clopidogrel absorption, Clinical Pharmacology & Therapeutics, vol.80, issue.5
DOI : 10.1016/j.clpt.2006.07.007

T. Simon, C. Verstuyft, and M. Mary-krause, Genetic Determinants of Response to Clopidogrel and Cardiovascular Events, New England Journal of Medicine, vol.360, issue.4, p.36375, 2009.
DOI : 10.1056/NEJMoa0808227

G. Biondi-zoccai, M. Lotrionte, and P. Agostoni, Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes, International Journal of Cardiology, vol.150, issue.3, pp.325-356, 2011.
DOI : 10.1016/j.ijcard.2010.08.035

K. Mahaffey, D. Wojdyla, and K. Carroll, Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial, Circulation, vol.124, issue.5, pp.544-54, 2011.
DOI : 10.1161/CIRCULATIONAHA.111.047498